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Other names: TAN1; hN1; notch1; Notch1 
Location: 9q34.3 
DNA/RNA 
Note: History and nomenclature: the notch1 gene, 
previously referred to as TAN1, was first described in 
1917 by American giant of genetics and embryology 
Thomas Hunt Morgan in a strain of the fruit fly 
Drosophila melanogaster with 'notches' apparent in 
their wings. Molecular study of the notch1 gene 
product and sequencing was carried out in the 1980s. 
The following discussion will refer to the notch1 gene 
as 'notch1' and the functional gene product (protein) as 
'NOTCH1'. 
Description 
Notch1 encompasses 51,418 bp of DNA on 
chromosome 9 (9q34.3) between 138,508,717 and 
138,508,135 bp from pter. 
Transcription 
The notch1 RNA transcript contains 34 exons and is 
9,371 bp in length. 
Protein 
Description 
The notch1 gene product NOTCH1 (2,556 amino acids; 
272,500 Da) consists of a large extracellular unit which 
associates in a calcium-dependent, non-covalent 
interaction with a second unit consisting of the 
following: a small extracellular region, a single 
transmembrane spanning region, and a small 
intracellular region. 
The NOTCH1 extracellular domain is composed 
primarily of 36 small cysteine knot motifs called EGF-
like repeats. Each EGF-like repeat is approximately 40 
amino acids, and its structure is defined largely by six 
conserved cysteine residues that form three conserved 
disulfide bonds. This feature is critical in ligand 
binding. The extracellular domain also contains three 
cysteine-rich Notch/Lin12 (LN) repeats required for the 
blockage of signaling in the absence of ligand. 
The NOTCH1 intracellular domain (NICD) contains a 
RAM23 domain, six ankyrin/cdc10 repeats involved in 
protein-protein interactions, two nuclear localization 
signals (N1 and N2), a transcriptional activation 
domain (TAD), and a PEST (proline-, glutamic acid-, 
serine-, and threonine-rich) sequence that negatively 
regulates protein stability. NOTCH1 undergoes an 
initial proteolytic cleavage by furin (PACE1) in the 
Golgi during trafficking to the cell surface. 
NOTCH1 is subject to several important post-
translational modifications. An O-glucose sugar may be 
added between the first and second conserved cysteine, 
and an O-fucose may be added between the second and 
third conserved cysteine. These sugars are added by an 
as yet unidentified O-glucosyltransferase, and GDP-
fucose protein O-fucosyltransferase 1 (POFUT1) 
respectively. The addition of O-fucose by POFUT1 is 
crucial for NOTCH1 function, and without its addition 
NOTCH1 proteins fail to function properly. As yet, the 
manner in which the glycosylation of NOTCH1 affects 
function is not completely understood. 
The O-glucose on NOTCH1 can be further elongated to 
a trisaccharide with the addition of two xylose sugars 
by xylosyltransferases, and the O-fucose can be 
elongated to a tetrasaccharide by the ordered addition  
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of an N-acetylglucosamine (GlcNAc) sugar by an N-
Acetylglucosaminyltransferase called Fringe, the 
addition of a galactose by a galactosyltransferase, nd 
the addition of a sialic acid by a sialyltransferas. 
The NOTCH1 ligands are single-pass transmembrane 
proteins and are members of the DSL 
(Delta/Serrate/LAG-2) family of proteins. In 
Drosophila there are two involved ligands named Delta 
and Serrate. In mammals, the corresponding names are 
Delta-like and Jagged. In mammals there are multiple 
Delta-like and Jagged ligands, as well as probably  
variety of other ligands, such as F3/contactin. 
Localisation 
NOTCH1: cell membrane. Single pass type I 
membrane protein. 
NICD: internal surface of cell membrane translocating 
to the nucleus upon ligand binding. 
Function 
The NOTCH1 cell signaling mechanism is conserved 
in most multicellular organisms including all 
metazoans (and thus vertebrates). NOTCH1 functions 
as a receptor for membrane-bound ligands Jagged1, 
Jagged2, and Delta1 in regulation of cell-fate 
determination. 
Once the NOTCH1 extracellular domain interacts with 
a ligand, an ADAM-family metalloprotease called 
TACE (Tumor Necrosis Factor Alpha Converting 
Enzyme) cleaves the NOTCH1 protein just outside the 
membrane. Consequently, the extracellular portion of 
NOTCH1 is released and continues to interact with the 
ligand. The ligand plus the NOTCH1 extracellular 
domain is then endocytosed by the ligand-expressing 
cell. There may be signaling effects in the ligand-
expressing cell after endocytosis, however currently 
these effects are not well understood. 
Upon ligand activation and cleavage via gamma 
secretase, the released notch intracellular domain 
(NICD) forms a transcriptional activator complex via 
its RAM23 domain with the transcription factor CSL 
(CBF1 in humans, RBP-JK in mice, Suppressor of 
Hairless in Drosophila, LAG in Caenorhabditis 
elegans). In the absence of NOTCH1, CSL proteins 
bind to promoters of target genes and recruit histone 
deacetylases and corepressors (CoR) that inhibit 
transcription of these genes. Among known corepresso  
molecules are SMRT/NcoR and SHARP/MINT/SPEN. 
The NICD/CSL interaction converts CSL from a 
transcriptional repressor into a transcriptional activ tor 
(CBF1 binding complex in humans) by displacing the 
corepressor complex and recruiting coactivators such as 
Mastermind-Like 1 (MAM) and histone 
acetyltransferase. 
Several other proteins are known to affect NOTCH1 
signaling, including the RING-domain E3 ubiquitin 
ligase deltex and the phosphotyrosine binding domain 
(PTB)-containing proteins numb and numblike, which 
act as context-dependent negative or positive Notch1 
regulators. 
In mammals there are three Fringe N-
acetylglucosamine (GlcNAc)-transferase enzymes 
named Lunatic Fringe, Manic Fringe, and Radical 
Fringe, which are responsible for something called the 
'Fringe Effect' on NOTCH1 signaling. If Fringe adds a 
GlcNAc to the O-fucose sugar, then addition of a 
galactose and sialic acid will occur. In the presence of 
this tetrasaccharide, NOTCH1 signals strongly when it 
interacts with the Delta ligand, but is inhibited when 
interacting with the Jagged ligand. The means by which 
this addition of sugar inhibits signaling through one 
ligand, and potentiates signaling through another is not 
clearly understood. 
Known target genes of NOTCH1 signaling include: 
members of the basic helix-loop-helix (bHLH) 
hairy/enhancer of split (Hes) family, the related 
HRT/Herp (Hes-related repressor protein) transcription 
factor family, the cell cycle regulator p21, the Notch 
pathway element Notch-regulated ankyrin repeat 
protein (Nrarp), deltex1, and the pre- T cell receptor-
alpha gene. 
The NOTCH1 signaling pathway is important for cell-
cell communication, involving gene regulation 
mechanisms that control multiple cell differentiation 
processes during embryonic and adult life. NOTCH1 
signaling is known to play a role in the following 
processes: 
Neuronal function and development: via lateral 
inhibition, NOTCH1 in the embryo generates 
molecular differences between adjacent cells. In the 
central nervous system, NOTCH1 activity maintains 
the neural progenitor state and inhibits differentiation. 
During gliogenesis, NOTCH1 has an instructive role, 
directly promoting the differentiation of different glial 
subtypes. More detailed analyses have also revealed 
that Notch regulates progenitor pool diversification and 
neuronal maturation. New data suggests that NOTCH1 
activity has a role in neuronal function of the adult 
brain. 
Modulating arterial endothelial fate and angiogenesis: 
expression of NOTCH1 and its ligand in vascular 
endothelium and defects in vascular phenotypes of 
targeted mutants in the NOTCH1 pathway suggest a 
critical role for NOTCH1 signaling in vasculogenesis 
and angiogenesis. Vascular endothelial growth factor 
(VEGF) can induce gene expression of NOTCH1 and 
its ligand, Delta-like 4 (Dll4), in human arterial 
endothelial cells. The VEGF-induced specific signaling 
is mediated through VEGF receptors 1 and 2 
(FLT1/VEGFR1 and KDR/VEGFR2) and is 
transmitted via the phosphatidylinositol 3-kinase/Akt 
pathway. Constitutive activation of NOTCH1 signaling 
stabilizes network formation of endothelial cells on
Matrigel and enhances formation of vessel-like 
structures in a three-dimensional angiogenesis model. 
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Blocking Notch signaling can inhibit network 
formation. 
Regulating cell communication events between 
endocardium and myocardium during ventricular 
chamber formation: ventricular chamber 
morphogenesis is critical for proper cardiac function 
and embryonic viability and depends on cellular 
interactions between the endocardium and 
myocardium. Ventricular Notch1 activity is highest at 
presumptive trabecular endocardium. RBPJk and 
Notch1 mutants show impaired trabeculation and 
marker expression, weakened EphrinB2, NRG1, and 
BMP10 expression and signaling, and decreased 
myocardial proliferation. Functional and molecular 
analyses have shown that Notch1 inhibition prevents 
EphrinB2 expression, and that EphrinB2 is a direct 
Notch1 target acting upstream of NRG1 in the 
ventricles. 
Cell lineage specification of both endocrine and 
exocrine pancreas: multiple cell types of the pancreas 
appear asynchronously during embryogenesis, which 
requires that pancreatic progenitor cell potential 
changes over time. Loss-of-function studies have 
shown that NOTCH1 signaling modulates the 
differentiation of these progenitors. It has been 
demonstrated that misexpression of activated NOTCH1 
in Pdx1-expressing progenitor cells prevents 
differentiation of both exocrine and endocrine lineag s. 
Progenitors remained trapped in an undifferentiated 
state even if notch1 activation occurred long after the 
pancreas was specified. Endocrine differentiation is 
associated with escape from this activity, as Ngn3-
expressing endocrine precursors were susceptible to 
notch1 inhibition, whereas fully differentiated 
endocrine cells were resistant. 
Notch1-dependent bone morphogenic protein (BMP) 
signaling: NOTCH1 enhances BMP2-induced 
commitment to the osteoblastic lineage during bone 
development. 
Regulation of cell-fate decision in the mammary gland: 
it has been suggested that Notch1 signaling plays a 
critical role in normal human mammary development 
by acting on both stem cells and progenitor cells, 
affecting self-renewal and lineage-specific 
differentiation. Notch signaling can act on mammary 
stem cells to promote self renewal and on early 
progenitor cells to promote their proliferation, as 
demonstrated in one study by a 10-fold increase in 
secondary mammosphere formation upon addition of a 
Notch activating DSL peptide. The same study showed 
that in addition to acting on stem cells, Notch signaling 
is also able to act on multipotent progenitor cells, 
facilitating myoepithelial lineage-specific commitment 
and proliferation. Stimulation of this pathway also 
promotes branching morphogenesis in three-
dimensional Matrigel cultures. Notch1 signaling hasno 
such effect on fully committed, differentiated,  
 
mammary epithelial cells. 
Cytoskeletal component formation: it has been 
suggested that NOTCH1 signaling, via some non-
nuclear mechanisms, controls the actin cytoskeleton 
through the tyrosine kinase Abl. 
Normal lymphocyte function: NOTCH1 signaling is 
involved in the maturation of both CD4+ and CD8+ 
cells in the thymus. In altered form, NOTCH1 may 
contribute to transformation or progression in some T-
cell neoplasms. NOTCH1 may be important for 
follicular differentiation and possibly cell fate slection 
within the follicle. 
Regulation of fate choices in the inner ear. 
Induction of left-right asymmetry. 
Regulation of limb bud development. 
Regulation of kidney development. 
Mutations 
Note: Notch1 mutant mice display defects in somite 
morphology. 
Mutations in the NOTCH1 ligand JAG1 affect the 
development of many organs, including that of the 
liver, skeleton, heart and eye. 
Mutations in the NOTCH1 ligand DLL3 result in rib 
fusions and trunk dwarfism. 
Notch1 mutations play a dual role in carcinogenesis a  
either a tumor suppressor or an oncogene. The role of 
NOTCH1 within and between cells depends on signal 
strength, timing, cell type, and context. 
Notch1 mutant cells infected with a retrovirus 
transducing the ras oncogene and injected 
subcutaneously into nude mice form aggressive 
squamous cell carcinoma (SCC), whereas wild-type 
cells do not. Loss of notch1 activity may thus cooperate 
with ras oncogene transformation in keratinocyte tumor 
development. 
In humans, aberrant NOTCH1 expression has been 
identified as a causative factor in the development of T-
cell acute lymphoblastic leukemia and lymphoma (T-
ALL). Recurrent t(7;9) translocation that involves the 
extracellular heterodimerization domain and/or the C-
terminal PEST domain of NOTCH1 is associated with 
T-ALL. The t (7; 9) translocation in T-ALL patients i  
characterized by juxtaposition of the 3' portion of the 
human notch1 gene with the T cell receptor beta 
(TCRB) locus. This leads to expression of truncated 
NOTCH1 transcripts and consequent production of 
dominant active, ligand-independent forms of the 
NOTCH1 receptor, causing T-ALL. Less than 1% of 
human T-ALLs exhibit the t(7;9) translocation, 
however, activating mutations in notch1 independent of 
t(7;9) have been identified in more than 50% of human 
T-ALL. 
Cells that are mutant for notch1 form skin and corneal 
tumors in mice, indicating that Notch1 signaling 
suppresses tumorigenesis in these instances. 
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Notch1 mutations cause an early developmental defect 
in the aortic valve and a later derepression of calcium 
deposition that causes progressive aortic valve disase. 
Many other human and murine cancers, including 
certain neuroblastomas, mammary, skin, cervical and 
prostate cancers are correlated with alterations in 
expression of Notch proteins and/or ligands. These 
cases await better characterization, but these 
observations suggest broad roles for Notch dysfunctio  
in a wide range of neoplasms. 
Based on analysis of neuroendocrine tumors and cell 
lines, NOTCH1 appears to be absent in this type of 
cancer. Expression of ectopic NOTCH1 in human 
medullary thyroid carcinoma and carcinoid tumor cell 
lines resulted in suppression of cancer cell growth. 
These data suggest that in neuroendocrine malignancies 
notch1 may act as a tumor suppressor. 
Implicated in 
Medullary thyroid cancer (MTC) 
Disease 
A neuroendocrine tumor (NET) derived from 
parafollicular C cells of the thyroid, MTC is the third 
most common form of thyroid cancer accounting for 3-
5% of all thyroid cancers. Symptoms include airway 
obstruction and diarrhea. MTC typically secretes the
bioactive hormone calcitonin. Currently, surgery is the 
only curative therapy for these patients, consisting of 
total thyroidectomy with lymph node dissection. 50% 
of these patients suffer persistent disease. 
Oncogenesis 
20% of patients with MTC have an autosomal 
dominant inherited form of the disease, which has been 
shown to be the result of well-characterized point 
mutations in the RET-protooncogene. The results of 
human MTC tissue sample analysis revealed an 
absence of active NOTCH1 protein in all tumors tested 
whereas NET markers such as chromogranin A (CgA) 
and ASCL1 were highly expressed. Activation of 
doxycycline-inducible notch1 in MTC cells by varying 
concentrations of doxycycline led to a dose-dependent 
increase in NOTCH1 protein and HES-1 protein 
expression. The level of ASCL1 was reduced with 
increase in NOTCH1. Further, it was observed that 
activation of notch1 significantly reduced the growth of 
MTC cells and the reduction in growth was dependent 
on the level of active NOTCH1 protein. NOTCH1 also 
down-regulates aberrant calcitonin secretion in a dose-
dependent manner. 
Gastrointestinal (GI) carcinoid tumors 
Disease 
GI carcinoids are rare tumors that arise from the diffuse 
neuroendocrine tissue of the gut with a reported 
incidence of 1-8 per 100,000. They frequently 
metastasize to the liver and are the second most 
common source of isolated liver metastases. GI 
carcinoids secrete various bioactive hormones such as 
5-HT (serotonin) and CgA. Patients with hepatic 
metastases suffer debilitating symptoms such as 
abdominal pain, flushing, bronchoconstriction, and 
diarrhea. Standard palliative treatment for these 
hormone-induced symptoms includes somatostatin 
analogs (such as octeotride). 
Oncogenesis 
RT-PCR reactions for various Notch receptors and 
ligands showed the presence of transcripts for notch1, 
notch2, notch3 and DLL1 in all carcinoid tumors 
tested. The human pancreatic carcinoid BON cell line
also showed detectable amounts all three NOTCH 
receptors (1-3). An absence of active NOTCH1 
intracellular domain (NICD) protein in BON cells was 
noted, suggesting that the NOTCH1 signaling pathway 
is inactive in carcinoids. Transient expression of active 
NOTCH1 via adenoviral vector in BON cells resulted 
in growth suppression and significant reduction in NET 
markers such as 5-HT, CgA, synaptophysin, neuron 
specific enolase (NSE), and ASCL1, confirming the 
tumor suppressor role of Notch1 signaling in carcinoid 
tumors. Further, it was shown that the reduction in 
serotonin is at the level of transcription of trypto han 
hydroxylase 1 mRNA suggesting that NOTCH1 
signaling regulates tryptophan hydroxylase 1, a rate-
limiting enzyme in 5-HT biosynthesis. In addition, 
stable expression of a NOTCH1 fusion protein in BON 
cells also resulted in high levels of functional NOTCH1 
that led to an increase in the level of HES-1, an 
immediate downstream NOTCH1 effector. Increases in 
the level of HES-1 significantly reduced the level of 
ASCL1 protein. Similar to transient adenoviral 
NOTCH1 activation, the stable expression of NOTCH1 
in BON cells also caused reductions in the levels of 
serotonin, CgA, NSE, and synaptophysin. 
Treatment of human carcinoid cancer cells with histone 
deacetylase (HDAC) inhibitors resulted in activation of 
NOTCH1 signaling and inhibition of carcinoid cell 
growth in vitro and in vivo. These findings suggest that 
NOTCH1 activation with HDAC inhibitors may be an 
attractive approach for the treatment of these tumors. 
Small-cell lung cancer (SCLC) 
Disease 
SCLC tends to present with metastatic and regional 
spread. SCLC is extremely aggressive and is 
characterized by rapid growth and early metastases. 
SCLC arises from major bronchi, and expresses NSE, 
CgA, and synaptophysin. 
Oncogenesis 
Similar to the observations in other neuroendocrine 
tumors such as carcinoids and MTC, neither the Notch1 
nor the raf-1 pathway is active in SCLC cells. In 
addition, these tumors express high levels of ASCL1. 
Inhibition of ASCL1 expression by anti sense or RNA 
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interference has been shown to suppress the growth f 
SCLC cells and reduce expression of NET markers, 
furthering the idea that ASCL1 plays a critical role in 
SCLC development. 
RNA interference against ASCL1 significantly 
inhibited growth both in vitro and in vivo xenograft 
model. It was also demonstrated that the growth 
inhibition by suppression of ASCL1 is mediated by cell
cycle arrest and apoptotic cell death. It is also kn wn 
that NOTCH1 is a negative regulator of ASCL1 and it 
is inactive in various SCLC cell lines tested. 
Adenoviral mediated expression of active NOTCH1 in 
these cell lines resulted in both NET marker reduction 
and growth suppression. Furthermore, the reduction in 
ASCL1 by Notch1 is achieved both at the level of 
transcription and post-translational degradation of the 
ASCL1 protein. These results further confirm that the
Notch1 pathway is not active in SCLC at baseline. 
Activation of NOTCH1 signaling in SCLC led to 
growth inhibition and NET marker reduction, 
suggesting a tumor suppressor role for notch1 in SCLC. 
T cell malignancies. 
Disease 
Human acute T cell acute lymphoblastic 
leukemia/lymphoma (T-ALL) is the prototypical 
notch1-associated cancer. The disease constitutes 
approximately 15 or 20% of ALL in children and 
adults. 
Oncogenesis 
Oncogenesis is attributed to constitutively active 
notch1 due to t(7;9) (q34:q34.3) activating mutations. 
This leads to expression of NICD in a T cell receptor-
beta-regulated manner. Although the t(7; 9) mutation is 
rare (less that 1% of T-ALL), the majority of human T-
ALL have gain-of-function mutations in notch1, 
leading to aberrant increases in downstream signaling. 
B-cell malignancies 
Disease 
Several mature B-cell and therapy-resistant B-cell 
malignancies have been shown to be susceptible to 
NOTCH1-mediated growth inhibition/apoptosis 
including Hodgkin, myeloma, and mixed-lineage 
leukemia (MLL)-translocated cell lines. These results 
suggest that therapies capable of activating Notch/Hes1 
signaling may have therapeutic potential in a wide 
range of human B-cell malignancies. 
In direct contrast to the previously mentioned studies, 
several groups have reported NOTCH1-mediated 
growth proliferation in such B cell malignancies as
multiple myeloma and Hodgkin and anaplastic large 
cell lymphoma. 
Oncogenesis 
Several studies support the existence of a dual-role for 
NOTCH1 signaling as either a tumor suppressor or 
oncogene in malignant B cells. These studies conflict, 
indicating that more definitive research is needed. A 
reasonably comprehensive study targeted the effect of 
Notch activation in multiple murine and human B-cell 
tumors, representing both immature and mature 
subtypes. They found that expression of constitutively 
active, truncated forms of several mammalian Notch 
receptors (including NOTCH1) inhibited growth and 
induced apoptosis in both murine and human B-cell 
lines. Similar results were obtained in human precursor 
B-cell acute lymphoblastic leukemia lines when Notch 
activation was achieved by coculture with fibroblasts 
expressing the Notch ligands Jagged1 or Jagged2. 
Truncated NOTCH1 receptors, as well as the Jagged 
ligands, induced HES-1 transcription. Retroviral 
expression of Hairy/Enhancer of Split-1 (HES-1) 
recapitulated the NOTCH1 effects, suggesting that 
HES-1 is an important mediator of NOTCH1-induced 
growth arrest and apoptosis in B cells. 
Breast cancer 
Disease 
Breast cancer is the most commonly diagnosed 
malignancy in women after skin cancer, and is a 
leading cause of cancer death in women from western 
countries. 
Oncogenesis 
NOTCH1 is over-expressed in solid tumors of the 
breast in the human model. Moreover, NOTCH1 
expression is increased in poorly differentiated tumors. 
A separate study found that elevated coexpression of 
the NOTCH1 ligand Jagged1 and NOTCH1 is 
characteristic of a subclass of breast cancer with a very 
poor outcome. Patients with tumors expressing high 
levels of JAG1 or NOTCH1 had a significantly poorer 
overall survival compared with patients expressing low 
levels of these genes (5-year survival rate of 42% 
versus 65% and median survival of 50 versus 83 
months, respectively, for JAG1 (High vs. Low) (P = 
0.01); 49% versus 64% and 53 versus 91 months, 
respectively, for NOTCH1 (High vs. Low) (P = 0.02)). 
Moreover, a synergistic effect of high-level JAG1 and 
high-level NOTCH1 coexpression on overall survival 
was observed (5-year survival rate of 32% and median 
survival of 40 months; P = 0.003). 
Skin cancer 
Disease 
In basal cell carcinoma (BCC), the most common non-
melanocytic human skin cancer, hyperplasic cell 
division may lead to invasion of the dermis by 
epidermal tissues. NOTCH1 signaling has been linked 
to BCC. NOTCH1 signaling has also been linked to 
primary melanoma. Melanomas originate from 
pigment-producing melanocytes. In human skin, 
melanocytes are positioned at the epidermal-dermal 
junction and are interspersed every 5 to 10 basal 
keratinocytes. 
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Oncogenesis 
Notch1 is implicated differentially as an oncogene i  
melanocyte-derived carcinoma and as a tumor 
suppressor gene in keratinocyte-derived carcinoma. 
Notch1 may act as a tumor suppressor gene in basal 
cell carcinoma (BCC). This conclusion was drawn from 
the observation that when keratinocytes were 
hyperproliferating, as in BCC, notch1 expression was 
essentially absent. 
A study showed that blocking NOTCH1 signaling 
suppressed, whereas constitutive activation of the 
NOTCH1 pathway enhanced, primary melanoma cell 
growth both in vitro and in vivo yet had little effct on 
metastatic melanoma cells. Activation of NOTCH1 
signaling enabled primary melanoma cells to gain 
metastatic capability. Furthermore, the oncogenic effect 
of notch1 on primary melanoma cells was mediated by 
beta-catenin, which was upregulated following notch1 
activation. Inhibiting beta-catenin expression revesed 
notch1-enhanced tumor growth and metastasis. Another 
study continued, finding that NOTCH1 signaling drives 
the vertical growth phase (VGP) of primary melanoma 
toward a more aggressive phenotype. Constitutive 
activation of NOTCH1 by ectopic expression of the 
NICD enables VGP primary melanoma cell lines to 
proliferate in a serum-independent and growth factor-
independent manner in vitro and to grow more 
aggressively with metastatic activity in vivo. They 
show that notch1 activation also enhances tumor cell 
survival when cultured as three-dimensional spheroids. 
Such effects of NOTCH1 signaling are mediated by 
activation of the mitogen-activated protein kinase 
(MAPK) and Akt pathways. Both pathways are 
activated in melanoma cells following Notch1 pathway 
activation. Inhibition of either the MAPK or the 
phosphatidylinositol 3-kinase (PI3K)-Akt pathway 




Cervical carcinomas are a major type of epithelial 
keratinocyte-derived tumors. Infection with human 
papillomaviruses (HPVs), more specifically the high-
risk HPV16 and HPV18, is associated with most 
cervical cancer and is thought to have a causal link with 
the disease. 
Oncogenesis 
NOTCH1 signaling is believed to play an oncogenic 
role in early disease stages and a tumor suppressive 
role in late disease stages. 
Immunohistochemical data have indicated that notch1 
expression is elevated in squamous metaplasia of the 
columnar epithelium, and in early HPV-induced lesion  
(CINI-III) and well-differentiated superficial 
carcinomas of the cervix. A study shows that in 
invasive cervical cancers, notch1 expression is 
substantially reduced. This dual-role pattern of notch1 
expression suggests that the protein may play an 
oncogenic function in the early stages of cervical 





EMT occurs during tumor progression when cells from 
a primary epithelial tumor change phenotype, become 
mesenchymal, and disseminate as single carcinoma 
cells, invading other organs as metastases. EMT may 
also be involved in the dedifferentiation program that 
leads to malignant carcinoma. 
Oncogenesis 
Jagged1 activation of endogenous Notch receptors in 
human endothelial cells promotes EMT in endothelial 
cells. NICD induction in the human adenocarcinoma 
cell line MCF7 promotes migratory behavior associated 
with E-CADHERIN loss. 
TGFb is another well-known inducer of EMT during 
embryonic development and the later stages of tumor 
progression. One possible mechanism of Notch-
induced tumor development and progression may 
involve modulation of the TGFb signaling pathway, as 
it has been suggested that TGFb may be Notch-
dependent. 
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